Here’s what you need to know about the new flu vaccines for over-65s

Prof Allen Cheng

writer

Prof Allen Cheng

Professor in Infectious Diseases Epidemiology, Monash University

Claim CPD for this activity

Educational Activities (EA)

0 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
0 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0 minutes

These are activities that require reflection on feedback about your work.

MO
0 minutes

These are activities that use your work data to ensure quality results.

Prof Allen Cheng

In an attempt to avoid a repeat of last year’s horror flu season, Health Minister Greg Hunt yesterday announced the government would fund two new flu vaccines in 2018 to try to better protect the elderly.

While influenza affects people of all ages, infections among the elderly are more likely to require hospitalisation or cause serious complications such as pneumonia and heart attacks. Of the 1,100 Australians who died last year from flu-related causes, 90% were aged 65 and over.

The two free vaccines for over-65s work in different ways: FluZone High Dose is a high-dose version; Fluad adds an additional ingredient to boost its effectiveness. Both are recommended for use only in people aged 65 and over. But neither is perfect. And it’s important to remember flu vaccines are, at best, only partially protective.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Fiona Chan

Dr Fiona Chan

Multiple Sclerosis vs Antibody Disease – What GPs Need to Know

Prof Andrew Sindone & Dr Ted Wu

Prof Andrew Sindone & Dr Ted Wu

Using SGLT2 to Reduce Cardiovascular Death in T2D – Important Updates for GPs

Prof Rod Baber

Prof Rod Baber

Menopause and MHT: Maximising Benefits & Minimising Risks

Dr Shannon Thomas

Dr Shannon Thomas

Peripheral Arterial Disease

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Prof Allen Cheng

writer

Prof Allen Cheng

Professor in Infectious Diseases Epidemiology, Monash University

Test your knowledge

Recent articles

Latest GP poll

Has a clinic you work at ever received an unfair negative online review?

Yes

0%

No

0%

Recent podcasts

Listen to expert interviews.
Click to open in a new tab

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease